Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated 16 enrolled M.D. Anderson Cancer Center Bristol-Myers Squibb · collab Iovance Biotherapeutics, Inc. · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.

Timeline

Start: 2018-10-16
Primary completion: 2024-08-21
Completion: 2024-08-21

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDA-TIL	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous
Background	aldesleukin	Protein / enzyme biologic	—	Intravenous

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications